Trial Profile
A Multinational, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Aripiprazole in Asian Pediatric Patients With Autism Spectrum Disorder and Behavior Problems
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2022
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Autistic disorder
- Focus Therapeutic Use
- 04 Oct 2022 Status changed from recruiting to completed.
- 01 Sep 2022 Results assessing the long-term improvement and safety of aripiprazole in treating irritability in Asian children and adolescents (6-17 years) with autistic disorder, published in the Journal of Child and Adolescent Psychopharmacology.
- 18 Mar 2014 New trial record